{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:06:32Z","timestamp":1777961192886,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970186"],"award-info":[{"award-number":["81970186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Advanced Innovation Center Research Foundation","award":["10287"],"award-info":[{"award-number":["10287"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The more selective second-generation BTK inhibitors (BTKi) Acalabrutinib and Zanubrutinib and the first-generation BTKi Ibrutinib are highlighted by their clinical effectiveness in mantle cell lymphoma (MCL), however, similarities and differences of their biological and molecular effects on anti-survival of MCL cells induced by these BTKi with distinct binding selectivity against BTK remain largely unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>AlamarBlue assays were performed to define cytotoxicity of BTKi against MCL cells, Jeko-1 and Mino. Cleaved PARP and caspase-3 levels were examined by immunoblot analysis to study BTKi-induced apoptotic effects. Biological effects of BTKi on MCL-cell chemotaxis and lipid droplet (LD) accumulation were examined in Jeko-1, Mino and primary MCL cells via Transwell and Stimulated Raman scattering imaging analysis respectively. Enzyme-linked immunoassays were used to determine CCL3 and CCL4 levels in MCL-cell culture supernatants. RNA-seq analyses identified BTKi targets which were validated by quantitative RT-PCR (qRT-PCR) and immunoblot analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Acalabrutinib and Zanubrutinib induced moderate apoptosis in Ibrutinib high-sensitive JeKo-1 cells and Ibrutinib low-sensitive Mino cells, which was accompanied by cleaved PARP and caspase-3. Such effects might be caused by the stronger ability of Ibrutinib to upregulate the expression of pro-apoptotic genes, such as <jats:italic>HRK, GADD45A<\/jats:italic>, and <jats:italic>ATM<\/jats:italic>, in JeKo-1 cells than in Mino cells, and the expression of such apoptotic genes was slightly changed by Acalabrutinib and Zanubrutinib in both JeKo-1 and Mino cells. Further, Acalabrutinib, Zanubrutinib and Ibrutinib reduced MCL-cell chemotaxis with similar efficiency, due to their similar abilities to downmodulate chemokines, such as CCL3 and CCL4. Also, these three BTKi similarly suppressed MCL-cell LD accumulation via downregulating lipogenic factors, DGAT2, SCD, ENPP2 and ACACA without significant differences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>BTKi demonstrated differential capacities to induce MCL-cell apoptosis due to their distinct capabilities to regulate the expression of apoptosis-related genes, and similar biological and molecular inhibitory effects on MCL-cell chemotaxis and LD accumulation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08475-3","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T10:03:11Z","timestamp":1624701791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhuojun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanshi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-6270","authenticated-orcid":false,"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"20","key":"8475_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"1","key":"8475_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-017-0533-9","volume":"10","author":"M Fichtner","year":"2017","unstructured":"Fichtner M, Dreyling M, Binder M, Trepel M. The role of B cell antigen receptors in mantle cell lymphoma. J Hematol Oncol. 2017;10(1):164. https:\/\/doi.org\/10.1186\/s13045-017-0533-9.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"8475_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148\u201367. https:\/\/doi.org\/10.1038\/nrc.2017.121.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8475_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","volume":"11","author":"S Balaji","year":"2018","unstructured":"Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M. NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol. 2018;11(1):83. https:\/\/doi.org\/10.1186\/s13045-018-0621-5.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"8475_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.028.","journal-title":"Leuk Res"},{"issue":"14","key":"8475_CR6","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412\u201324. https:\/\/doi.org\/10.1182\/blood-2013-02-482125.","journal-title":"Blood"},{"issue":"13","key":"8475_CR7","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","volume":"113","author":"JA Burger","year":"2009","unstructured":"Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050\u20138. https:\/\/doi.org\/10.1182\/blood-2008-07-170415.","journal-title":"Blood"},{"issue":"5","key":"8475_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjh.13659","volume":"171","author":"K Takahashi","year":"2015","unstructured":"Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, et al. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015;171(5):726\u201335. https:\/\/doi.org\/10.1111\/bjh.13659.","journal-title":"Br J Haematol"},{"issue":"4","key":"8475_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SS Chen","year":"2016","unstructured":"Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833\u201343. https:\/\/doi.org\/10.1038\/leu.2015.316.","journal-title":"Leukemia"},{"issue":"1","key":"8475_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1146\/annurev-biochem-061009-102430","volume":"81","author":"TC Walther","year":"2012","unstructured":"Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem. 2012;81(1):687\u2013714. https:\/\/doi.org\/10.1146\/annurev-biochem-061009-102430.","journal-title":"Annu Rev Biochem"},{"issue":"11","key":"8475_CR11","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1080\/10428194.2018.1439167","volume":"59","author":"U Rozovski","year":"2018","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, et al. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59(11):2686\u201391. https:\/\/doi.org\/10.1080\/10428194.2018.1439167.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"8475_CR12","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","volume":"23","author":"SEM Herman","year":"2017","unstructured":"Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, et al. The Bruton tyrosine kinase (BTK) inhibitor Acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0463.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8475_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139. https:\/\/doi.org\/10.1182\/blood.2019001160.","journal-title":"Blood"},{"issue":"4","key":"8475_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32(4):920\u201330. https:\/\/doi.org\/10.1038\/leu.2017.321.","journal-title":"Leukemia"},{"issue":"14","key":"8475_CR15","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","volume":"23","author":"V Patel","year":"2017","unstructured":"Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with Ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1446.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8475_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1509981.","journal-title":"N Engl J Med"},{"issue":"4","key":"8475_CR17","doi-asserted-by":"publisher","first-page":"e33738","DOI":"10.1371\/journal.pone.0033738","volume":"7","author":"P Gelebart","year":"2012","unstructured":"Gelebart P, Zak Z, Anand M, Belch A, Lai R. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One. 2012;7(4):e33738. https:\/\/doi.org\/10.1371\/journal.pone.0033738.","journal-title":"PLoS One"},{"issue":"4","key":"8475_CR18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/hon.2667","volume":"37","author":"YX Zou","year":"2019","unstructured":"Zou YX, Zhu HY, Li XT, Xia Y, Miao KR, Zhao SS, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Hematol Oncol. 2019;37(4):392\u2013400. https:\/\/doi.org\/10.1002\/hon.2667.","journal-title":"Hematol Oncol"},{"issue":"2","key":"8475_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","volume":"18","author":"CJ Li","year":"2019","unstructured":"Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, et al. Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther. 2019;18(2):267\u201377. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0478.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"8475_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1021\/jz200516n","volume":"2","author":"D Zhang","year":"2011","unstructured":"Zhang D, Slipchenko MN, Cheng JX. Highly sensitive vibrational imaging by femtosecond pulse stimulated Raman loss. J Phys Chem Lett. 2011;2(11):1248\u201353. https:\/\/doi.org\/10.1021\/jz200516n.","journal-title":"J Phys Chem Lett"},{"issue":"1","key":"8475_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1215637.","journal-title":"N Engl J Med"},{"issue":"1","key":"8475_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88\u201394. https:\/\/doi.org\/10.1200\/JCO.2012.42.7906.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8475_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","volume":"26","author":"DJ de Gorter","year":"2007","unstructured":"de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26(1):93\u2013104. https:\/\/doi.org\/10.1016\/j.immuni.2006.11.012.","journal-title":"Immunity"},{"issue":"10","key":"8475_CR24","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.celrep.2018.08.015","volume":"24","author":"D Ackerman","year":"2018","unstructured":"Ackerman D, Tumanov S, Qiu B, Michalopoulou E, Spata M, Azzam A, et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 2018;24(10):2596\u2013605 e2595. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.015.","journal-title":"Cell Rep"},{"issue":"9","key":"8475_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/carcin\/bgq131","volume":"31","author":"RA Igal","year":"2010","unstructured":"Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010;31(9):1509\u201315. https:\/\/doi.org\/10.1093\/carcin\/bgq131.","journal-title":"Carcinogenesis"},{"issue":"17","key":"8475_CR26","doi-asserted-by":"publisher","first-page":"8180","DOI":"10.1158\/0008-5472.CAN-07-0389","volume":"67","author":"A Beckers","year":"2007","unstructured":"Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007;67(17):8180\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0389.","journal-title":"Cancer Res"},{"issue":"1","key":"8475_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1042\/BST20110608","volume":"40","author":"M Gotoh","year":"2012","unstructured":"Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans. 2012;40(1):31\u20136. https:\/\/doi.org\/10.1042\/BST20110608.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"8475_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. 2014;166(6):849\u201361. https:\/\/doi.org\/10.1111\/bjh.12974.","journal-title":"Br J Haematol"},{"issue":"5","key":"8475_CR29","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.biocel.2008.06.018","volume":"41","author":"A Rosemary Siafakas","year":"2009","unstructured":"Rosemary Siafakas A, Richardson DR. Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol. 2009;41(5):986\u20139. https:\/\/doi.org\/10.1016\/j.biocel.2008.06.018.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"8475_CR30","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1073\/pnas.050400997","volume":"97","author":"C Schaffner","year":"2000","unstructured":"Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci. 2000;97(6):2773\u20138. https:\/\/doi.org\/10.1073\/pnas.050400997.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"8475_CR31","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/cdd.2011.17","volume":"18","author":"PN Kelly","year":"2011","unstructured":"Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18(9):1414\u201324. https:\/\/doi.org\/10.1038\/cdd.2011.17.","journal-title":"Cell Death Differ"},{"issue":"5","key":"8475_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182\u20139. https:\/\/doi.org\/10.1182\/blood-2011-10-386417.","journal-title":"Blood"},{"issue":"6","key":"8475_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","volume":"118","author":"J Saez de Guinoa","year":"2011","unstructured":"Saez de Guinoa J, Barrio L, Mellado M, Carrasco YR. CXCL13\/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood. 2011;118(6):1560\u20139.","journal-title":"Blood"},{"key":"8475_CR34","doi-asserted-by":"crossref","unstructured":"Luanpitpong S, Janan M, Thumanu K, Poohadsuan J, Rodboon N, Klaihmon P, et al. Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells. Cancers. 2019;11(4).","DOI":"10.3390\/cancers11040576"},{"key":"8475_CR35","first-page":"8619342","volume":"2018","author":"S Cui","year":"2018","unstructured":"Cui S, Zhang S, Yue S. Raman spectroscopy and imaging for Cancer diagnosis. J Healthc Eng. 2018;2018:8619342.","journal-title":"J Healthc Eng"},{"issue":"6","key":"8475_CR36","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.cmet.2018.04.004","volume":"27","author":"DG McLaren","year":"2018","unstructured":"McLaren DG, Han S, Murphy BA, Wilsie L, Stout SJ, Zhou H, et al. DGAT2 inhibition alters aspects of triglyceride metabolism in rodents but not in non-human primates. Cell Metab. 2018;27(6):1236\u201348 e1236. https:\/\/doi.org\/10.1016\/j.cmet.2018.04.004.","journal-title":"Cell Metab"},{"issue":"12","key":"8475_CR37","doi-asserted-by":"publisher","first-page":"11767","DOI":"10.1074\/jbc.M311000200","volume":"279","author":"SJ Stone","year":"2004","unstructured":"Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem. 2004;279(12):11767\u201376. https:\/\/doi.org\/10.1074\/jbc.M311000200.","journal-title":"J Biol Chem"},{"issue":"9","key":"8475_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4252\/wjsc.v11.i9.693","volume":"11","author":"RR Begicevic","year":"2019","unstructured":"Begicevic RR, Arfuso F, Falasca M. Bioactive lipids in cancer stem cells. World J Stem Cells. 2019;11(9):693\u2013704. https:\/\/doi.org\/10.4252\/wjsc.v11.i9.693.","journal-title":"World J Stem Cells"},{"issue":"10","key":"8475_CR39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrm3188","volume":"12","author":"WH Moolenaar","year":"2011","unstructured":"Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12(10):674\u20139. https:\/\/doi.org\/10.1038\/nrm3188.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"8475_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2141.2008.07325.x","volume":"143","author":"A Masuda","year":"2008","unstructured":"Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol. 2008;143(1):60\u201370. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07325.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"8475_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/hep.28973","volume":"65","author":"E Kaffe","year":"2017","unstructured":"Kaffe E, Katsifa A, Xylourgidis N, Ninou I, Zannikou M, Harokopos V, et al. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. Hepatology. 2017;65(4):1369\u201383. https:\/\/doi.org\/10.1002\/hep.28973.","journal-title":"Hepatology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08475-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T10:03:29Z","timestamp":1624701809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08475-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8475"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08475-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was authorized by the Ethics Committee of Beihang University. Full-term deliveries signed consent forms before they provided umbilical cord samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors gave permissions for publishing the manuscript in BMC Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"732"}}